Literature DB >> 27376752

[Pruritus in systemic diseases : Common and rare etiologies].

A E Kremer1, T Mettang2.   

Abstract

Chronic pruritus is a symptom of various internal disorders. In contrast to dermatological diseases, pruritus does not present with primary skin alterations in these patients. However, intense scratching may cause secondary skin changes such as abrasion, excoriation, prurigo nodularis, or in rare cases even scaring. The most common internal medicine causes for chronic pruritus are chronic kidney disease, hepatobiliary and hematological disorders as well as adverse drug reactions. Pruritus is less commonly seen in patients with endocrine or metabolic diseases, malabsorption syndromes, infectious diseases and solid tumors. The pathogenesis of pruritus in these disorders remains largely elusive, albeit preliminary insights have been gained for uremic and cholestatic pruritus. Antipruritic treatment is therefore symptomatic in most cases and may represent a clinical challenge. The calcium channel blockers gabapentin and pregabalin have the best proven efficacy in chronic kidney disease-associated pruritus. In Japan nalfurafine, a κ-opioid receptor agonist, has been licensed for this indication. UVB light may also attenuate uremic symptoms. In patients suffering from hepatobiliary disorders the sequestrant cholestyramine and the enzyme inducer rifampicin are effective. Furthermore, μ‑opioid receptor antagonists and sertraline may be used to ameliorate cholestatic pruritus. So far, no randomized controlled trials have been performed for chronic itch in other internal medicine disorders. Antipruritic treatment is mainly based on effective therapy of the underlying disease.

Entities:  

Keywords:  Cholestasis; Chronic kidney disease; Itch; Lymphoproliferative disease; Underlying disease

Mesh:

Substances:

Year:  2016        PMID: 27376752     DOI: 10.1007/s00105-016-3826-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

Review 1.  Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis.

Authors:  E A Jones; N V Bergasa
Journal:  Can J Gastroenterol       Date:  2000-01       Impact factor: 3.522

2.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

3.  Skin signs in anorexia nervosa.

Authors:  R Strumìa; E Varotti; E Manzato; M Gualandi
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

4.  Prevalence of chronic itch and associated factors in haemodialysis patients: a representative cross-sectional study.

Authors:  Melanie Weiss; Thomas Mettang; Ulrich Tschulena; Jutta Passlick-Deetjen; Elke Weisshaar
Journal:  Acta Derm Venereol       Date:  2015-09       Impact factor: 4.437

5.  The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.

Authors:  Martin Kimmel; Dominik Mark Alscher; Robert Dunst; Niko Braun; Christoph Machleidt; Thomas Kiefer; Christina Stülten; Heiko van der Kuip; Christiane Pauli-Magnus; Ulrich Raub; Ulrich Kuhlmann; Thomas Mettang
Journal:  Nephrol Dial Transplant       Date:  2005-10-25       Impact factor: 5.992

6.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

Review 7.  Pruritus in the older patient: a clinical review.

Authors:  Timothy G Berger; Melissa Shive; G Michael Harper
Journal:  JAMA       Date:  2013-12-11       Impact factor: 56.272

Review 8.  Advances in pathogenesis and management of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ruth Bolier; Remco van Dijk; Ronald P J Oude Elferink; Ulrich Beuers
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

9.  A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy.

Authors:  Dirk R Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Yves Vanrenterghem
Journal:  Nephrol Dial Transplant       Date:  2004-05-18       Impact factor: 5.992

10.  Severe pruritus should be a B-symptom in Hodgkin's disease.

Authors:  P G Gobbi; G Attardo-Parrinello; G Lattanzio; S C Rizzo; E Ascari
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.